| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 8 | 223.2x | 17.8x | Bottom tier | |
Growth | 71 | 16.5% | 7.1% | Top tier | |
Quality | 61 | 1.9% | 4.5% | Around median | |
Safety | 85 | — | 2.6x | Top tier | |
Capital Return | 50 | — | 2.12% | Around median | |
Momentum | 81 | 34.6% | 2.9% | Top tier | |
Sentiment | 67 | 12 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Repligen Corporation operates in bioprocessing technologies, generating revenue from the sale of consumables, capital equipment, and services used in filtration, chromatography, proteins, and process analytics. Its portfolio drivers include prepacked OPUS columns, ATF systems for process intensification, SoloVPE PLUS instruments, FlowVPX technologies, and real-time analytics, while serving biopharmaceutical companies, contract development and manufacturing organizations, emerging biotechnology companies, and OEM customers across multiple regions. In Q1 fiscal 2026, consumables, including proteins, achieved double-digit growth, services grew by more than 30%, and analytics led performance with growth exceeding 50%.
Q1 fiscal 2026 revenue was approximately $194 million, up 15% on a reported basis and 11% organically, with foreign exchange contributing three percentage points of growth and an inorganic contribution from two months of the initial analytics acquisition. Revenue was geographically distributed as 46% from North America, 37% from Europe, the Middle East, and Africa, and approximately 17% from Asia-Pacific and the rest of the world; the latter region grew by more than 25%, while revenue in China nearly doubled compared with a low base period.
Adjusted gross profit was $108 million in Q1 fiscal 2026, with a margin of 55.5%, up 180 basis points, driven by volume leverage, pricing, and product mix. Adjusted operating income was $30 million, up 28%, with an operating margin of 15.4% and year-over-year expansion of 160 basis points; adjusted net income was also $27 million, and adjusted diluted earnings per share were $0.48, representing increases of 22% and 23%, respectively.
The analyst consensus is “Buy,” with an average price target of $152 and a target range of $142 to $160; the average is below the 52-week range high of $188.73, while the annual range extends from $100.99 to $188.73. No positive price-to-earnings multiple is available in the provided data, while the $9.9 billion market capitalization equals approximately 11.9–12.3 times fiscal 2026 revenue guidance, placing substantial weight on continued organic growth and margin expansion. The valuation is supported by the increase in adjusted earnings per share guidance to $1.97–$2.05, but ATF timing risks, quarterly margin normalization, and competition in China limit reliance on the consensus target alone.
Figures in the text are as of 2026-08-29; the live price is shown at the top of the page.
Repligen achieved organic growth of 11% and revenue of $194 million in Q1 fiscal 2026. Analytics led performance with growth exceeding 50%, driven by demand for SoloVPE PLUS and upgrades, while chromatography grew by more than 25% due to OPUS columns. The company is guiding to reported and organic growth of 9%–13% and revenue of $803–$833 million in fiscal 2026.
Adjusted gross margin was 55.5%, up 180 basis points, and adjusted operating margin reached 15.4%, up 160 basis points. Adjusted operating income increased 28% to $30 million, and adjusted net income increased 22% to $27 million. The company raised its fiscal 2026 adjusted earnings per share guidance to $1.97–$2.05, but expects the benefit from production cost absorption to normalize during the remainder of the year.
Analytics grew by more than 50% in Q1 fiscal 2026, and downstream analytics recorded a record quarter supported by SoloVPE PLUS. The company integrated FlowVPX into its downstream filtration system and is working to expand integration into upstream applications and introduce digital twin capabilities from Novasign into small-scale filtration systems. Management expects analytics growth to exceed 20% in fiscal 2026 as the upgrade cycle continues and the contribution from upstream products increases.
Automated analysis for informational purposes only — not investment advice.
Revenue in China nearly doubled in Q1 fiscal 2026 compared with a low base period, making it the company’s best quarter in the country in more than two years. In 2026, Repligen signed a multi-phase, multi-product OEM partnership to increase its competitiveness and enable local manufacturing starting in 2027, with an initial focus on filtration consumables. The partnership did not contribute to Q1 fiscal 2026 results, and the Chinese market is also experiencing stronger local competition that requires successful execution of the localization strategy.
ATF grew across equipment and consumables during Q1 fiscal 2026, but two customers are managing inventory associated with two commercial drugs, reducing the company’s expectations for the franchise during the year. This is compounded by a headwind from a specific gene therapy program, so management expects filtration growth in the mid-single digits in fiscal 2026. Management believes the needs of the two drugs and the expansion of ATF use in other products could become supportive in 2027, but the timing of this shift depends on customers drawing down inventory and executing their programs.
